Skip to contentB
Biofrontera Inc.
B
BFRIBiofrontera Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$10.59M$10.59Mderived+4.4% vs Q4 2022 Net Income$3.53M$3.53MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biofrontera Inc. · CIK 1858685 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,866,000N/M Operating Cash Flowderived-$8,866,000N/M Free Cash Flowderived-$8,857,000N/M Margins · derivedOperating margin-36.5%+18.9 pt vs Q4 2022
Net margin33.3%+60.7 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 15, 2024 · 75 d after period end